Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacokinetic mechanisms and drug interactions without systematic methodology.
PubMed 23703578 · doi:10.1007/s40262-013-0075-4
What was done
This paper reviewed the pharmacokinetic mechanisms and drug-drug interactions between seven HMG-CoA reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin) and antiviral protease inhibitors used for HIV (ritonavir- or cobicistat-boosted regimens) and hepatitis C virus (boceprevir, telaprevir), focusing on cytochrome P450 3A metabolism and OATP1B1 transporter pathways.
What was found
The abstract reports no numerical pharmacokinetic values or effect sizes. Qualitatively, simvastatin and lovastatin have the highest potency for interaction with strong CYP3A inhibitors (ritonavir, cobicistat, boceprevir, telaprevir) and their coadministration is contraindicated due to increased risk of skeletal muscle toxicity. Atorvastatin interactions are less potent. Non-CYP3A statin concentrations are also increased via OATP1B1 uptake transporter inhibition, requiring initiation at the lowest available dose.
Why it matters
Patients with HIV frequently require statin therapy for dyslipidemia, but coadministering statins with antiviral protease inhibitors can dramatically alter drug clearance. Understanding specific metabolic and transporter pathways prevents severe adverse events such as rhabdomyolysis.
Limits
As a narrative review, no systematic search strategy, meta-analysis, or quantitative data (such as AUC or Cmax fold-changes) are provided in the abstract. Clinical outcome data comparing safety across different statin regimens are not reported.
Cited by
- supports There are currently seven distinct statin medications approved and in clinical existence.